港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

恆瑞醫藥

55.150

+11.10025.20%

成交量：8,266.38萬

成交額：47.34億

市值：3,641.84億

市盈率：53.23

高：60.500

開：57.000

低：55.150

收：44.050

資料載入中...

總覽公司新聞公告

江蘇恆瑞醫藥股份有限公司藥品申請臨牀試驗默示許可獲受理

（創新驅動下的醫藥巨頭新徵程：恆瑞港股IPO啓航）

430億天價交易！中國創新藥隱形冠軍突襲全球，恆瑞醫藥之後的下一個神話？

价值事务所

恆瑞醫藥申請一種七氟烷的工業化製備方法專利，製得的七氟烷純度高

寧德時代、恆瑞醫藥香港上市表現亮眼！H股的估值要變天了？

恆瑞醫藥H股定價！每股44.05港元，90款創新藥管線曝光 →

3000億“藥茅”，來了

中国新闻周刊

創新藥黃金時代開啓！政策+技術+國際化三重驅動，恆瑞H股首日飆升37%領跑行業新週期

金融小博士

25 年後，恆瑞再次登陸資本市場

Insight数据库

典型醫藥串標案曝光！大批註射劑價格“跳水”，知名中藥企業“爆雷”，石藥、恆瑞大豐收

恆瑞醫藥引爆港股！上週7只基金扎堆申報，瞄準科技醫藥汽車

恆瑞醫藥H股今日在港交所掛牌上市募資約97.47億港元

中访网财观

剛剛，又一“巨無霸”成功上市！

AaronDing资产...

從連雲港到香港，恆瑞醫藥創下近五年港股醫藥最大IPO，募資總額近百億港元

每日经济新闻

恆瑞醫藥：赴港上市，業績亮眼國際化加速

3600億巨頭再敲鐘，要保“王冠”

中国企业家

恆瑞醫藥上市：市值3641億港元為近五年港股醫藥板塊最大IPO

66歲孫飄揚再次IPO敲鐘，3600億

恆瑞醫藥港股上市首日高開近三成，資本加碼助力加速國際化

赴港上市掀起高潮！年內第4只“AH”股誕生

东方财富研究中心

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/01276/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":55.15,"timestamp":1747987708026,"preClose":44.05,"halted":0,"volume":82663811,"delay":0,"floatShares":224519800,"shares":6603522074,"eps":1.036,"marketStatus":"未開盤","change":11.1,"latestTime":"05-23 16:08:28","open":57,"high":60.5,"low":55.15,"amount":4733500812,"amplitude":0.121453,"askPrice":55.5,"askSize":2200,"bidPrice":55.15,"bidSize":14200,"shortable":0,"etf":0,"ttmEps":1.036205539,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1748223000000},"marketStatusCode":0,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":44.05,"dividendRate":0.003941,"openAndCloseTimeList":[[1747963800000,1747972800000],[1747976400000,1747987200000]],"volumeRatio":0,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":54.5,"timestamp":1747983600000,"preClose":55.4,"halted":0,"volume":54184000,"delay":0,"premium":"-7.34"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":224519800,"roa":"8.99%","roe":"15.22%","lyrEps":1.036,"shares":6603522074,"dividePrice":0.218423,"high":60.5,"amplitude":0.121453,"preClose":44.05,"low":55.15,"week52Low":55.15,"pbRate":"7.10","psRate":"11.42","week52High":60.5,"institutionHeld":0,"latestPrice":55.15,"committee":0.731707,"eps":1.036,"divideRate":0.003961,"volume":82663811,"delay":0,"ttmEps":1.036205539,"open":57,"prevYearClose":44.05,"prevWeekClose":44.05,"prevMonthClose":44.05,"prevQuarterClose":44.05,"fiveDayClose":44.05,"twentyDayClose":44.05,"sixtyDayClose":44.05},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2538115196","title":"江蘇恆瑞醫藥股份有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2538115196","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538115196?lang=zh_tw&edition=fundamental","pubTime":"2025-05-25 12:26","pubTimestamp":1748147212,"startTime":"0","endTime":"0","summary":"5月25日，据CDE官网消息，江苏恒瑞医药股份有限公司联合申请药品“苹果酸法米替尼胶囊”，获得临床试验默示许可，受理号CXHL2500298。公示信息显示，药品“苹果酸法米替尼胶囊”适应症：本品联合SHR-A1811±阿得贝利单抗用于实体瘤的治疗。江苏恒瑞医药股份有限公司，成立于1997年，位于连云港市，是一家以从事医药制造业为主的企业。企业注册资本637900.2274万人民币，实缴资本6190万人民币。通过天眼查大数据分析，江苏恒瑞医药股份有限公司共对外投资了36家企业，参与招投标项目5000次，知识产权方面有商标信息396条，专利信息1517条，此外企业还拥有行政许可1563个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/25122650649614.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1576","LU0405327494.USD","LU1064130708.USD","LU1064131003.USD","03347","BK0188","BK0012","BK0239","LU1328615791.USD","BK0028","LU2488822045.USD","LU2328871848.SGD","BK0196","01276","600276","BK0060","LU1969619763.USD","BK1583","LU0405327148.USD","BK0183","LU2148510915.USD","BK1141"],"gpt_icon":0},{"id":"2538896115","title":"（創新驅動下的醫藥巨頭新徵程：恆瑞港股IPO啓航）","url":"https://stock-news.laohu8.com/highlight/detail?id=2538896115","media":"报告大厅","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538896115?lang=zh_tw&edition=fundamental","pubTime":"2025-05-25 11:20","pubTimestamp":1748143200,"startTime":"0","endTime":"0","summary":"中国报告大厅网讯，2025年5月23日，中国医药产业迎来历史性时刻——恒瑞医药正式登陆港交所。作为国内首个实现从仿制药向创新药全面转型的标杆企业，此次港股上市不仅为公司全球化布局注入新动能，更标志着中国医药行业在创新驱动下的高质量发展进入新阶段。这种全球化布局正推动恒瑞从国内领军者向国际参与者蜕变。总结来看，此次港股上市标志着恒瑞医药正式迈入资本全球化新阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505251139459764a15e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505251139459764a15e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1328615791.USD","BK0028","LU1064131003.USD","LU2328871848.SGD","BK0188","BK0183","LU1064130708.USD","LU0405327494.USD","01276","BK0239","LU2488822045.USD","BK0012","BK0196","600276","LU0405327148.USD","LU2148510915.USD","LU1969619763.USD","BK0060","159938"],"gpt_icon":0},{"id":"2537199929","title":"430億天價交易！中國創新藥隱形冠軍突襲全球，恆瑞醫藥之後的下一個神話？","url":"https://stock-news.laohu8.com/highlight/detail?id=2537199929","media":"价值事务所","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537199929?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 20:58","pubTimestamp":1748091537,"startTime":"0","endTime":"0","summary":"之所以突然涨那么多，主要是近期港股三生制药又爆出一笔天价BD交易，把旗下一款双抗SSGJ707授权给了辉瑞。与国外制药巨头相比，中国药企弯道超车选择了双抗这个赛道。ADC同样也是国内药企的优势领域，除了百利天恒，今年稍早些时候科伦博泰旗下的芦康沙妥珠单抗获批上市，成为了首个获得完全批准上市的国产ADC药物。随着双抗+ADC的不断突破，中国创新药企在国际制药舞台上的地位将会越来越重要。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524221354a48addaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524221354a48addaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2148510915.USD","LU1969619763.USD","LU1328615791.USD","BK0239","LU0405327494.USD","LU2328871848.SGD","BK0188","LU0405327148.USD","BK0183","LU2488822045.USD","BK0196","LU1064131003.USD","BK0028","600276","LU1064130708.USD","BK0012","BK0060","01276","159992"],"gpt_icon":0},{"id":"2537196419","title":"恆瑞醫藥申請一種七氟烷的工業化製備方法專利，製得的七氟烷純度高","url":"https://stock-news.laohu8.com/highlight/detail?id=2537196419","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537196419?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 20:41","pubTimestamp":1748090492,"startTime":"0","endTime":"0","summary":"金融界2025年5月24日消息，国家知识产权局信息显示，江苏恒瑞医药股份有限公司;上海恒瑞医药有限公司申请一项名为“一种七氟烷的工业化制备方法”的专利，公开号CN120025235A，申请日期为2025年04月。专利摘要显示，本公开涉及一种七氟烷的工业化制备方法。本公开所述的制备方法制得的七氟烷纯度高，收率高，浪费少，有利于工业化生产。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/05/24204150645883.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0183","01276","BK0060","LU1064131003.USD","LU1969619763.USD","LU1328615791.USD","LU2488822045.USD","600276","LU0405327494.USD","LU2148510915.USD","LU0405327148.USD","BK0196","BK0239","LU1064130708.USD","LU2328871848.SGD","BK0028","BK0188","BK0012"],"gpt_icon":1},{"id":"2537816052","title":"寧德時代、恆瑞醫藥香港上市表現亮眼！H股的估值要變天了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2537816052","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537816052?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 15:32","pubTimestamp":1748071920,"startTime":"0","endTime":"0","summary":"最新加入这一行列的是江苏恒瑞医药股份有限公司，该公司是中国市值最大的制药商。宁德时代和恒瑞医药的强劲表现，正值近几周中国股市全面复苏之际，这得益于中美贸易休战以及中国政府为刺激经济增长而采取的新举措。根据恒生沪深港通中国AP溢价指数，H股整体仍较A股折价32%，而3月份的低点为28% 。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052415435595012d94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052415435595012d94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0607220059.USD","LU2360107325.USD","LU2153592121.USD","LU0181495838.USD","LU1997245094.SGD","300750","LU0054450605.USD","LU0149534421.HKD","LU2476274308.USD","LU1328277881.USD","01276","LU0516422366.SGD","LU0821914370.USD","LU2153591404.USD","600276","LU0051755006.USD","LU2399975544.HKD","LU2778985437.USD","LU0531971595.HKD","LU1861214812.USD","IE0003851619.USD","LU1146622755.USD","LU2275660780.HKD","LU2488822045.USD","LU1769817096.USD","LU2506951792.HKD","LU0011963245.USD","LU1820825898.SGD","LU0405327148.USD","IE0003795394.USD","LU0164865239.USD","LU1719994722.HKD","LU0823414551.USD","LU0449515922.USD","LU0828237510.HKD","LU2097828805.USD","LU0327786744.USD","LU0516423091.SGD","EVS.SI","LU0543330483.HKD","LU0328353924.USD","SGXZ49509284.SGD","IE00BPRC5H50.USD","LU1831875114.USD","03750","LU0348805143.USD","LU1188198961.HKD","LU0140636845.USD","BK0012","LU0516422952.EUR","LU1720050803.USD"],"gpt_icon":1},{"id":"2537167001","title":"恆瑞醫藥H股定價！每股44.05港元，90款創新藥管線曝光 →","url":"https://stock-news.laohu8.com/highlight/detail?id=2537167001","media":"谈思生物","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537167001?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 15:02","pubTimestamp":1748070137,"startTime":"0","endTime":"0","summary":"公司计划将94.58亿港元募资用于研发及全球布局，持续推动创新药发展。5月21日，恒瑞医药对外宣布，其H股发行的最终定价为每股44.05港元，并计划于5月23日在香港联交所主板正式挂牌交易。据此前公告，恒瑞医药本次H股全球发售的基础发行数量为224,519,800股。在2024年，恒瑞医药提交了8项创新药的新药上市申请。进入2025年第一季度，恒瑞医药的收入达到72.06亿元，同比增长20.1%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524153242a6eb2675&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524153242a6eb2675&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","LU2148510915.USD","LU1064131003.USD","BK0028","BK0060","LU2328871848.SGD","159992","BK0196","BK0239","BK0012","BK0183","01276","LU0405327494.USD","LU1328615791.USD","BK0188","LU0405327148.USD","600276","LU1064130708.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2537476164","title":"3000億“藥茅”，來了","url":"https://stock-news.laohu8.com/highlight/detail?id=2537476164","media":"中国新闻周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537476164?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 12:02","pubTimestamp":1748059368,"startTime":"0","endTime":"0","summary":"中国药企出海依旧任重道远在国内A股市场，恒瑞医药被称为“药茅”。药智数据显示，2016—2023年，恒瑞销售额前十名的品种均突破了50亿元大关，前三名国内公立医疗机构销售额更是超过百亿元。5月23日，恒瑞医药港股首日挂牌上市，首秀大涨约30%，获454.85倍超额认购。2024年，恒瑞医药实现营收279.85亿元，归母净利润63.37亿元。而在截至2025年3月31日的2024财年中，武田总营收达到了45798亿日元，核心营业利润为11626亿日元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524124523a6eb07f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524124523a6eb07f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","LU1064131003.USD","399300","LU0405327494.USD","BK0060","159982","BK0196","BK0028","LU2148510915.USD","BK0183","LU1064130708.USD","LU2328871848.SGD","LU1969619763.USD","LU0405327148.USD","BK0188","600276","LU2488822045.USD","01276","BK0012","LU1328615791.USD"],"gpt_icon":0},{"id":"2537167605","title":"創新藥黃金時代開啓！政策+技術+國際化三重驅動，恆瑞H股首日飆升37%領跑行業新週期","url":"https://stock-news.laohu8.com/highlight/detail?id=2537167605","media":"金融小博士","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537167605?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 11:23","pubTimestamp":1748057006,"startTime":"0","endTime":"0","summary":"创新药板块步入快速放量期，行业盈利能力明显增强。H股上市亮点发售价44.05港元，H股折价率超25%吸引资金流入，午盘涨幅30.87%，换手率超30%。布局小核酸药物，聚焦慢乙肝临床治愈及肝脏疾病领域。总结：创新药板块处于“政策+技术+国际化”三重驱动下的黄金周期，短期关注H股上市催化、业绩超预期标的，中长期布局ADC、GLP-1等前沿赛道龙头，警惕研发与政策风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524145936a48a8aea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524145936a48a8aea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1328615791.USD","600276","LU1064131003.USD","LU1969619763.USD","BK0183","LU2328871848.SGD","159992","BK0012","BK0060","BK0239","BK0188","LU0405327148.USD","01276","LU2148510915.USD","LU0405327494.USD","BK0028","LU1064130708.USD","BK0196","LU2488822045.USD"],"gpt_icon":0},{"id":"2537165678","title":"25 年後，恆瑞再次登陸資本市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2537165678","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537165678?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 08:31","pubTimestamp":1748046703,"startTime":"0","endTime":"0","summary":"5 月 23 日，恒瑞正式在港交所敲钟上市了，融资金额高达100 亿港元。作为国内医药行业的老大哥，恒瑞家底本身就非常厚实。再加上港股 IPO 募集到的资金，在未来很长时间里，这些足以支持恒瑞走向国际化的野心。招股书里提到，恒瑞计划将此次募集资金净额的一半用于创新药临床研究，1/5 用于创新药开发和技术平台升级。从这也可以看出，恒瑞剑指全球市场的国际化野心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524090003a6eadd2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"908ca084d7278b880acaab9313f78dbb","theme_name":"🔥熱榜No.29 · 恆瑞醫藥在港上市創紀錄","theme_type":2,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524090003a6eadd2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1064130708.USD","BK0183","LU1064131003.USD","LU1969619763.USD","LU2488822045.USD","BK0060","LU1328615791.USD","LU2328871848.SGD","BK0012","LU0405327494.USD","LU0405327148.USD","BK0028","BK0188","BK0239","LU2148510915.USD","BK0196","600276","01276"],"gpt_icon":0},{"id":"2537166337","title":"典型醫藥串標案曝光！大批註射劑價格“跳水”，知名中藥企業“爆雷”，石藥、恆瑞大豐收","url":"https://stock-news.laohu8.com/highlight/detail?id=2537166337","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537166337?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 08:10","pubTimestamp":1748045449,"startTime":"0","endTime":"0","summary":"211个药品申请降价5月20日，云南省药品集中采购平台发布通知，公示企业申请降价情况。知名中药企业“爆雷”5月21日，华神科技公告称，公司及相关责任人近日被四川证监局责令改正，相关责任人被出具警示函。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524092748a6eae2fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524092748a6eae2fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YR35.GBP","561510","IE00B543WZ88.USD","LU1226288170.HKD","562390","BK1515","LU1960683339.HKD","LU1226288253.USD","LU1152091168.USD","LU1951186391.HKD","BK1161","IE00BZ08YT58.USD","LU0072913022.USD","BK1191","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","LU1226287792.SGD","LU0501845795.SGD","LU0880133367.SGD","IE0008369823.USD","BK1574","09939","BK1521","LU0326950275.SGD","LU1152091754.HKD","LU1993786604.SGD","SG9999004220.SGD","600276","LU0140636845.USD","LU0067412154.USD","01276","LU1226287529.USD","IE0008368742.USD","IE00B031HY20.USD","LU1226287875.USD","LU1008478684.HKD","01093","LU1807302812.USD"],"gpt_icon":0},{"id":"2537716368","title":"恆瑞醫藥引爆港股！上週7只基金扎堆申報，瞄準科技醫藥汽車","url":"https://stock-news.laohu8.com/highlight/detail?id=2537716368","media":"华夏时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537716368?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 08:01","pubTimestamp":1748044867,"startTime":"0","endTime":"0","summary":"5月23日，A股创新药龙头企业恒瑞医药登陆香港联交所主板，首日开盘涨幅超30%，前日暗盘交易涨幅达30%，市场热度折射出资金对港股创新药板块的强烈关注。与此同时，机构投资者加速抢滩港股通产品线，上周共有7只港股通主题基金密集申报，涵盖创新药、科技、汽车等热门赛道，另有8只已申报产品获受理，港股结构性机会持续吸引资金关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202505243413624216.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505243413624216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","HSCEI","YANG","01276","BK1515","HSTECH","09939","BK4614","BK1161"],"gpt_icon":1},{"id":"2537615671","title":"恆瑞醫藥H股今日在港交所掛牌上市 募資約97.47億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537615671","media":"中访网财观","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537615671?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 01:15","pubTimestamp":1748020500,"startTime":"0","endTime":"0","summary":"本次全球发售H股总数为224,519,800股，发行价为每股44.05港元，募集资金净额约97.47亿港元。H股上市后，公司总股本增至6,603,522,074股，其中A股占比96.6%，H股占比3.4%。若超额配售权悉数行使，总股本将进一步提升至6,637,199,874股。恒瑞医药表示，H股上市有助于拓宽国际融资渠道，提升全球品牌影响力，进一步推动创新药研发和国际化战略布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2025-05-24/doc-inexqsvs8361330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["01276","BK0188","LU1064131003.USD","BK0196","LU1064130708.USD","LU2148510915.USD","BK0239","LU0405327148.USD","LU1328615791.USD","LU2328871848.SGD","BK0183","LU1969619763.USD","600276","LU2488822045.USD","BK0060","BK0012","BK0028","LU0405327494.USD"],"gpt_icon":1},{"id":"2537129157","title":"剛剛，又一“巨無霸”成功上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2537129157","media":"AaronDing资产...","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537129157?lang=zh_tw&edition=fundamental","pubTime":"2025-05-24 00:01","pubTimestamp":1748016073,"startTime":"0","endTime":"0","summary":"若全额行使超额配售权及发售量调整权，发行H股最高达296,927,200股，最高募资额可达130.8亿港元。这意味着此次恒瑞医药募资额将成为近五年港股医药企业IPO最高募资额。创新药销售收入占总收入的百分比由2022年的38.1%增至2023年的43.4%，并进一步增至2024年的46.3%。由于上述原因，公司的毛利由截至2024年3月31日止三个月的人民币50.55亿元增加21.4%至2","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524051536a6eab6e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524051536a6eab6e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01477","BK1161","BK1191","01276","06978"],"gpt_icon":1},{"id":"2537306561","title":"從連雲港到香港，恆瑞醫藥創下近五年港股醫藥最大IPO，募資總額近百億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537306561","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537306561?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 22:33","pubTimestamp":1748010801,"startTime":"0","endTime":"0","summary":"据悉，恒瑞医药此次全球发售H股总数约2.25亿股，发行价44.05港元，募资总额约98.90亿港元。值得一提的是，戴洪斌的角色在恒瑞医药港股上市前夕已有所调整。恒瑞医药港股上市现场事实上，恒瑞医药此次赴港上市并非孤例，而是近年来A股创新药企借助香港联交所平台加快国际化布局的缩影。对恒瑞医药而言，本次上市不仅是募资手段，更是其国际化战略的重要支点。在业绩层面，BD授权收入已对恒瑞医药形成显著业绩贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052322344997635d8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"92258637d6ff1e9cb4f4844790de8572","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052322344997635d8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276"],"gpt_icon":1},{"id":"2537371751","title":"恆瑞醫藥：赴港上市，業績亮眼 國際化加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2537371751","media":"和讯网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537371751?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 21:51","pubTimestamp":1748008278,"startTime":"0","endTime":"0","summary":"恒瑞医药此次发行价每股44.05港元，为发行区间上限定价。其IPO是近五年港股医药板块最大IPO，也是2025年度第二大港股IPO。港股上市4个多月，获国际热烈响应，基石投资者有GIC、景顺等知名机构。恒瑞医药创立于1970年，2000年在上交所上市。2024年营收、净利创新高，今年一季度业绩增长。此次赴港上市是其出海战略关键一步，可提升全球品牌影响力，强化国际化制药集团定位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523215352a489caa4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"92258637d6ff1e9cb4f4844790de8572","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523215352a489caa4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","LU1064130708.USD","LU2148510915.USD","BK0188","BK0060","LU2488822045.USD","LU1328615791.USD","LU1064131003.USD","LU1969619763.USD","LU2328871848.SGD","LU0405327494.USD","BK0012","BK0196","01276","BK0239","LU0405327148.USD","600276","BK0183"],"gpt_icon":0},{"id":"2537134757","title":"3600億巨頭再敲鐘，要保“王冠”","url":"https://stock-news.laohu8.com/highlight/detail?id=2537134757","media":"中国企业家","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537134757?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 21:37","pubTimestamp":1748007441,"startTime":"0","endTime":"0","summary":"根据协议，三生制药将获得12.5亿美元不可退还且不可抵扣的首付款，以及最高可达48亿美元的里程碑付款。截至发稿，股价55.15港元，市值达3642亿港元。恒瑞被投资者质疑“保守”。当前，创新药行业已经“群星”闪耀，进入了高度战备状态。两人以2000亿元财富值位列《2020胡润全球富豪榜》中国第4位，全球第35位。这让时年63岁的孙飘扬不得不回归“救火”。恒瑞整体营收达到279.85亿元，增速22.63%，净利润63.37亿元，增速高达47.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052321384195007f4c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052321384195007f4c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399300","BK0196","159982","BK0060","LU1064131003.USD","LU1064130708.USD","LU2148510915.USD","LU2328871848.SGD","BK0183","LU1328615791.USD","BK0239","LU0405327148.USD","BK0012","BK0028","LU0405327494.USD","LU2488822045.USD","BK0188","01276","LU1969619763.USD","600276"],"gpt_icon":0},{"id":"2537134034","title":"恆瑞醫藥上市：市值3641億港元 為近五年港股醫藥板塊最大IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2537134034","media":"雷递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537134034?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 21:32","pubTimestamp":1748007149,"startTime":"0","endTime":"0","summary":"恒瑞医药IPO成近五年港股医药板块最大IPO，也是目前2025年度第二大港股IPO。恒瑞医药开盘价为57港元，较发行价上涨29%；收盘价为55.15港元，较发行价上涨25%；以收盘价计算，，公司市值约3641亿港元。恒瑞医药2024年营收为279.85亿元，同比增22.63%；归母净利润为63.37亿元，同比增47.28%；恒瑞医药2025年第一季度营收为72亿元，同比增20%；归母净利润为18.74亿元，同比增36.90%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523213526a489c600&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"92258637d6ff1e9cb4f4844790de8572","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523213526a489c600&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276"],"gpt_icon":1},{"id":"2537856152","title":"66歲孫飄揚再次IPO敲鐘，3600億","url":"https://stock-news.laohu8.com/highlight/detail?id=2537856152","media":"医深观","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537856152?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 20:53","pubTimestamp":1748004794,"startTime":"0","endTime":"0","summary":"据悉，本次港股IPO,恒瑞发行价44.05港元，开盘后公司股价立刻大涨近3成。截至收盘，恒瑞港股市值3642亿港元，直接缔造2025年最大医药IPO。2020年初，恒瑞医药市值突破4000亿元。财报显示，恒瑞医药2021年营收259.06亿元，同比下降6.59%，净利润45.30亿元，同比暴跌28.41%，这是恒瑞医药首份营收与净利润均同比降低的年报。2021年8月，孙飘扬被迫再度出山，重新掌舵恒瑞医药。在今天的港股上市仪式上，66岁的孙飘扬亲自敲响了恒瑞的开市锣。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524034026a48a0e51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250524034026a48a0e51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0060","LU0405327494.USD","LU1969619763.USD","LU1064131003.USD","600276","LU1064130708.USD","01276","BK0028","BK0196","BK0183","LU1328615791.USD","BK0239","LU0405327148.USD","LU2488822045.USD","BK0012","BK0188","LU2328871848.SGD","LU2148510915.USD"],"gpt_icon":0},{"id":"2537139588","title":"恆瑞醫藥港股上市首日高開近三成，資本加碼助力加速國際化","url":"https://stock-news.laohu8.com/highlight/detail?id=2537139588","media":"观察者网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537139588?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 20:06","pubTimestamp":1748001960,"startTime":"0","endTime":"0","summary":"恒瑞医药此次全球发售H股总数为2.245亿股，发行价定于区间上限44.05港元，募资净额约94.58亿港元。作为国内头部药企，恒瑞医药近年来业绩稳健增长。恒瑞医药的港股上市标志着其全球化布局的重要一步。港股市场汇聚了众多国际投资者，这将有助于恒瑞医药提升国际品牌影响力，优化全球品牌形象。然而，恒瑞医药在国际化进程中仍面临众多挑战。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"92258637d6ff1e9cb4f4844790de8572","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-05-23/doc-inexqhfw5891885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0060","HSCEI","BK0012","LU2328871848.SGD","BK0196","LU2148510915.USD","LU2488822045.USD","BK0183","LU0405327494.USD","BK4614","LU0405327148.USD","LU1969619763.USD","LU1064131003.USD","LU1328615791.USD","LU1064130708.USD","BK0028","600276","HSTECH","BK0188","YANG","01276"],"gpt_icon":1},{"id":"2537613349","title":"赴港上市掀起高潮！年內第4只“AH”股誕生","url":"https://stock-news.laohu8.com/highlight/detail?id=2537613349","media":"东方财富研究中心","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537613349?lang=zh_tw&edition=fundamental","pubTime":"2025-05-23 18:59","pubTimestamp":1747997954,"startTime":"0","endTime":"0","summary":"A股上市公司，正在掀起一波赴港的上市高潮。继宁德时代之后，5月23日（周五），医药巨头恒瑞医药正式登陆港交所，成为年内第4只“AH”股。上市首日，恒瑞医药港股暴涨25.20%，最新总市值达3642亿港元。恒瑞医药能有如此表现的原因或与以下三点有关：一是公司本身质量颇佳；二是2025年以来港股上演了一场“创新药牛市”，港股创新药指数今年涨超30%；三是港股IPO赚钱效应持续凸显，赤峰黄金、钧达股份、宁德时代等上市后股价均有优异表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523190951a48999ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523190951a48999ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["399300","159982","600276","03750","01276"],"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":1,"totalSize":207,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.3182,"buy":0.4091,"hold":0.2273,"sell":0.0455,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4091,"analysts":22,"updateTime":1743523200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2025-05-23","current":52.570963,"percent":0,"low":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"high":53.632028,"avg":53.101495,"sd":0.530532,"marketCap":390693388207.53},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53}],"updateTime":1748171518645}}}